Premium
Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: A study in a real life population
Author(s) -
Van Puyvelde Katrien,
Mets Tony
Publication year - 2011
Publication title -
geriatrics and gerontology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 57
eISSN - 1447-0594
pISSN - 1444-1586
DOI - 10.1111/j.1447-0594.2010.00674.x
Subject(s) - galantamine , rivastigmine , medicine , donepezil , observational study , activities of daily living , cholinesterase , alzheimer's disease , disease , dementia , incidence (geometry) , prospective cohort study , clinical global impression , psychiatry , alternative medicine , physics , optics , placebo , pathology
Aim: To record in real life the appreciation of elderly patients, their caregivers and physicians of a once daily formulation of prolonged release of galantamine in the treatment of mild to moderate Alzheimer's disease. Methods: A prospective, multicenter, observational study was conducted in 128 elderly patients, treated for 6 months with galantamine, donepezil or rivastigmine. Results: Of the patients treated with galantamine, 82 of the 97 (84.5%) were continuing their treatment after 6 months. These patients reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well ( P < 0.001). The incidence of serious side‐effects possibly related to galantamine was 9.3%, which was not different from that in patients treated with other cholinesterase inhibitors. Conclusion: In a real life setting, galantamine once daily is safe and is favorably appreciated by patients, their caregivers and physicians. Geriatr Gerontol Int 2011; 11: 256–261.